BICX News and Press, BioCorRx Inc. From 05/17/22

BioCorRx press release (OTCQB:BICX): Q1 GAAP EPS of -$0.14. Revenue of $0.02M (+100.0% Y/Y). For further details see: BioCorRx GAAP EPS of -$0.14, revenue of $0.02M

ANAHEIM, CA - ( NewMediaWire ) - May 17, 2022 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the first quarter ended March 31, 2022 and repor...

BioCorRx (OTCQB:BICX) said it began the recruiting and enrollment process for its first-in-human trial of BICX104, an implantable biodegradable naltrexone pellet to treat opioid use disorder (OUD). The phase 1 study will be in two parallel groups of randomized healthy volunteers to evalu...

ANAHEIM, CA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has begun the recruiting a...

ANAHEIM, CA / ACCESSWIRE / April 26, 2022 / BioCorRx Inc. (OTCQB:BICX) (the "Company") , a developer and provider of innovative treatment programs fr substance abuse and related disorders, today announced that it will present at the Planet MicroCap Showcase 2022 on Wednesday, May 4, 2022 at 3...

Phoenix, Arizona--(Newsfile Corp. - April 19, 2022) - The Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) ("the Company"), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Director, CEO, and CFO of the Com...

ANAHEIM, CA - ( NewMediaWire ) - April 11, 2022 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has been awarded a supplemental grant of approximately ...

ANAHEIM, CA - ( NewMediaWire ) - April 01, 2022 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a year-end business update for 2021 and reported on recent corpo...

ANAHEIM, CA - ( NewMediaWire ) - March 22, 2022 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that management will be participating in two upcoming conferenc...

BioCorRx (OTCQB:BICX) received approval from an independent institutional review board to begin a phase 1 trial of its therapy BICX104, an implantable biodegradable naltrexone pellet to treat opioid use disorder. Naltrexone is used to manage alcohol or opioid use disorder by re...